Lipocine Inc. (NASDAQ:LPCN) announced its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.01, Bloomberg Earnings reports.

Lipocine (NASDAQ:LPCN) remained flat at $4.49 during mid-day trading on Tuesday. The company’s stock had a trading volume of 46,117 shares. The stock’s market capitalization is $86.48 million. The firm’s 50 day moving average is $4.36 and its 200-day moving average is $3.96. Lipocine has a one year low of $3.03 and a one year high of $5.90.

A number of analysts recently weighed in on LPCN shares. Roth Capital set a $38.00 price target on shares of Lipocine and gave the company a “buy” rating in a report on Tuesday, June 20th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Lipocine in a report on Wednesday, April 26th. Finally, Canaccord Genuity set a $10.00 target price on shares of Lipocine and gave the stock a “buy” rating in a report on Monday, April 24th.

ILLEGAL ACTIVITY NOTICE: “Lipocine Inc. (LPCN) Issues Earnings Results” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Earnings History for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with's FREE daily email newsletter.